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Abstract 
The 1000 Genomes Project aims to provide a deep characterisation of human 
genome sequence variation as a foundation for investigating the relationship 
between genotype and phenotype.  We present results of the pilot phase of the 
project, designed to develop and compare different strategies for genome wide 
sequencing with high throughput sequencing platforms.  We undertook three 
projects: low coverage whole genome sequencing of 179 individuals from four 
populations, high coverage sequencing of two mother-father-child trios, and exon 
targeted sequencing of 697 individuals from seven populations.  We describe the 
location, allele frequency and local haplotype structure of approximately 15 million 
SNPs, 1 million short insertions and deletions and 20,000 structural variants, the 
majority of which were previously undescribed.  We show that over 95% of the 
currently accessible variants found in any individual are present in this dataset; on 
average, each person carries approximately 250 to 300 loss of function variants in 
annotated genes and 50 to 100 variants previously implicated in inherited disorders.  
We demonstrate how these results can be used to inform association and functional 
studies.  From the two trios we directly estimate the rate of de novo germline base 
substitution mutations to be approximately 10
-8 per base pair per generation.  We 
find many putative functional variants with large allele frequency differences between 
populations.  We explore the data with regard to signatures of natural selection, and 
identify a marked reduction of genetic variation in the neighbourhood of genes, due 
to selection at linked sites.  These methods and public data will support the next 
phase of human genetic research.  1000 Genomes paper. Last modified on 9/29/2010 
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Introduction 
Understanding the relationship between genotype and phenotype is one of the 
central goals in biology and medicine.  The reference human genome sequence
1 
provides a foundation for the study of human genetics, but systematic investigation 
of  human variation requires full knowledge of DNA sequence variation across the 
entire spectrum of allele frequencies and types of DNA differences.  Substantial 
progress has already been made.  By 2008 the public catalogue of variant sites 
(dbSNP 129) contained approximately 11 million single nucleotide polymorphisms 
(SNPs) and 3 million short insertions and deletions (indels)
2-4.  Databases of 
structural variants (SVs) (e.g., dbVAR) indexed the locations of large genomic 
variants.  The International HapMap Project catalogued both allele frequencies and 
the correlation patterns between nearby variants, a phenomenon known as linkage 
disequilibrium (LD), across several populations for 3.5 million SNPs
3, 4.  
These resources have driven disease gene discovery in the first generation of 
genome wide association studies (GWAS), wherein genotypes at several hundred 
thousand variant sites, combined with the knowledge of LD structure, allow the vast 
majority of common variants (here, those with > 5% minor allele frequency, or MAF) 
to be tested for association
4 with disease.  Over the last five years association 
studies have identified more than a thousand genomic regions associated with 
disease susceptibility and other common traits
5.   Genome wide collections of both 
common and rare SVs have similarly been tested for association with disease
6.   
Despite these successes, much work is still needed to achieve a deep understanding 
of the genetic contribution to human phenotypes
7.  Once a region has been identified 
as harbouring a risk locus, detailed study of all genetic variants in the locus is 
required to discover the causal variant(s), to quantify their contribution to disease 
susceptibility, and to elucidate their roles in functional pathways. Low frequency and 
rare variants (here defined as 0.5% to 5% MAF, and below 0.5% MAF respectively) 
vastly outnumber common variants and also contribute significantly to the genetic 
architecture of disease but it has not yet been possible to study them systematically
7-
9.  Meanwhile, advances in DNA sequencing technology have enabled the 1000 Genomes paper. Last modified on 9/29/2010 
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sequencing of individual genomes
10-13, illuminating the gaps in the first generation of 
databases that contain mostly common variant sites.  A much more complete 
catalogue of human DNA variation is a prerequisite to fully understanding the role of 
common and low frequency variants in human phenotypic variation. 
The aim of the 1000 Genomes Project is to discover, genotype and provide accurate 
haplotype information on all forms of human DNA polymorphism in multiple human 
populations.  Specifically, the goal is to characterise over 95% of variants that are in 
genomic regions accessible to current high throughput sequencing technologies and 
that have allele frequency of 1% or higher (the classical definition of polymorphism) 
in each of five major population groups (populations in or with ancestry from Europe, 
East Asia, South Asia, West Africa and the Americas).  Because functional alleles 
are often found in coding regions and have reduced allele frequencies, lower 
frequency alleles (down to 0.1%) will also be catalogued in such regions. 
Here we report the results of the pilot phase of the project, the aim of which was to 
develop and compare different strategies for genome wide sequencing with high 
throughput platforms. To this end we undertook three projects:  low coverage 
sequencing of 179 individuals, deep sequencing of six individuals in two trios, and 
exon sequencing of 906 genes in 697 individuals (Box 1).  The results give us a 
much deeper, more uniform picture of human genetic variation than was previously 
available, enabling new insights into the landscapes of functional variation, genetic 
association and natural selection in humans.1000 Genomes paper. Last modified on 9/29/2010 
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Box 1.  The 1000 Genomes pilot projects 
To develop and assess multiple strategies to detect and genotype variants of various 
types and frequencies using high throughput sequencing we carried out three 
projects, using samples from the extended HapMap collection
14 
•  Trio project:  whole genome shotgun sequencing at high coverage (average 
42x) of two families (one Yoruba from Ibadan, Nigeria: YRI, one of European 
ancestry in Utah: CEU), each including two parents and one daughter. Each 
of the offspring was sequenced using three platforms and by multiple centres.  
•  Low coverage project:  whole genome shotgun sequencing at low coverage 
(2-6x) of 59 unrelated individuals from YRI, 60 unrelated individuals from 
CEU, 30 unrelated Han Chinese individuals in Beijing (CHB) and 30 unrelated 
Japanese individuals in Tokyo (JPT).   
•  Exon project:  targeted capture of 8,140 exons from 906 randomly selected 
genes (total of 1.4 Mb) followed by sequencing at high coverage (average > 
50x) in 697 individuals from 7 populations of African (YRI, Luhya in Webuye, 
Kenya: LWK), European (CEU, Toscani in Italia: TSI) and East Asian (CHB, 
JPT, Chinese in Denver, Colorado: CHD) ancestry.  
The three experimental designs differ substantially both in their ability to obtain data 
for variants of different types and frequencies and in the analytical methods we used 
to infer individual genotypes.  The Figure shows a schematic representation of the 
projects and the type of information obtained from each.  Colours in the left region 
indicate different haplotypes in individual genomes, and line width indicates depth of 
coverage (not to scale).  The shaded region to the right gives an example of 
genotype data that could be generated for the same sample under the three 
strategies (dots indicate missing data, dashes indicate phase information, i.e., 
whether heterozygous variants can be assigned to the correct haplotype).  Within a 
short region of the genome, each individual carries two haplotypes, typically shared 
by others in the population.  In the trio design, high sequence coverage and the use 
of multiple platforms enable accurate discovery of multiple variant types across most 
of the genome, with Mendelian transmission aiding genotype estimation, inference of 1000 Genomes paper. Last modified on 9/29/2010 
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haplotypes and quality control.  The low coverage project, in contrast, efficiently 
identifies shared variants on common haplotypes
15, 16 (red or blue), but has lower 
power to detect rare haplotypes (light green) and associated variants (indicated by 
the missing alleles), and will give some inaccurate genotypes (indicated by the red 
allele incorrectly assigned G).  The exon design enables accurate discovery of 
common, rare and low frequency variation in the targeted portion of the genome, but 
lacks the ability to observe variants outside the targeted regions or assign haplotype 
phase. 
 1000 Genomes paper. Last modified on 9/29/2010 
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Results 
 
Overview of data generation, alignment and variant discovery 
A total of 4.9 Tb of DNA sequence was generated in nine sequencing centres using 
three sequencing technologies, from DNA obtained from immortalised 
lymphoblastoid cell lines (Table 1 and Supplementary Table 1).  All sequenced 
individuals provided informed consent and explicitly agreed to public dissemination 
of the variation data, as part of the HapMap Project (see Supplementary Information 
for details of informed consent and data release). The heterogeneity of the sequence 
data (read lengths from 25 to several hundred base pairs; single and paired end) 
reflects the diversity and rapid evolution of the underlying technologies during the 
project.  All primary sequence data were confirmed to have come from the correct 
individual by comparison to HapMap SNP genotype data. 
Analysis to detect and genotype sequence variants differed among variant types and 
the three projects, but all workflows shared four features: 
•  Discovery:  alignment of sequence reads to the reference genome and 
identification of candidate sites or regions at which one or more samples differ 
from the reference sequence. 
•  Filtering:  use of quality control measures to remove candidate sites that 
likely were false positives. 
•  Genotyping:  estimation of the alleles present in each individual at variant 
sites or regions.   
•  Validation:  assaying a subset of newly discovered variants using an 
independent technology, enabling the estimation of the false discovery rate.  
Independent data sources were used to estimate the accuracy of inferred 
genotypes.   1000 Genomes paper. Last modified on 9/29/2010 
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All primary sequence reads, mapped reads, variant calls, inferred genotypes, 
estimated haplotypes and new independent validation data are publically available 
through the project website (www.1000genomes.org); filtered sets of variants, allele 
frequencies and genotypes were also deposited in dbSNP 
(www.ncbi.nlm.nih.gov/snp). 
 
Alignment and the “accessible genome” 
Sequencing reads were aligned to the NCBI36 reference genome (details in 
Supplementary Information) and made available in the BAM file format
17, an early 
innovation of the project for storing and sharing high throughput sequencing data.  
Accurate identification of genetic variation depends on alignment of the sequence 
data to the correct genomic location.  We restricted most variant calling to the 
“accessible genome”, defined as that portion of the reference sequence that remains 
after excluding regions with many ambiguously placed reads or unexpectedly high or 
low numbers of aligned reads (Supplementary Information).  This approach balances 
the need to reduce incorrect alignments and false positive detection of variants 
against maximizing the proportion of the genome that can be interrogated  
For the low coverage analysis, the accessible genome contains approximately 85% 
of the reference sequence and 93% of the coding sequences.  Over 99% of sites 
genotyped in the second generation haplotype map (HapMap II)
4 are included.  Of 
inaccessible sites, over 97% are annotated as high copy repeats or segmental 
duplications.  However, only one quarter of previously discovered repeats and 
segmental duplications were inaccessible (Supplementary Table 2). Much of the 
data for the trio project was collected prior to technical improvements in our ability to 
map sequence reads robustly to some of the repeated regions of the genome 
(primarily longer, paired reads).  For these reasons, stringent alignment was more 
difficult and a smaller portion of the genome was “accessible” in the trio project: 80% 
of the reference, 85% of coding sequence and 97% of HapMap II sites (Table 1).  
 1000 Genomes paper. Last modified on 9/29/2010 
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Calibration, local realignment and assembly 
The quality of variant calls is influenced by many factors including the quantification 
of base calling error rates in sequence reads, the accuracy of local read alignment 
and the method by which individual genotypes are defined.  The project introduced 
key innovations in each of these areas (see Supplementary Information).  First, base 
quality scores reported by the image processing software were empirically 
recalibrated by tallying the proportion that mismatched the reference sequence (at 
non-dbSNP sites) as a function of the reported quality score, position in read and 
other characteristics.  Second, at potential variant sites local realignment of all reads 
was performed jointly across all samples, allowing for alternative alleles that 
contained indels.  This realignment step substantially reduced errors, because local 
misalignment, particularly around indels, can be a major source of error in variant 
calling.  Finally, by initially analysing the data with multiple genotype and variant 
calling algorithms and then generating a consensus of these results, the project 
reduced genotyping error rates by 40-50% compared to those currently achievable 
using any one of the methods alone (Supplementary Figure 1). 
We also used local realignment to generate candidate alternative haplotypes in the 
process of calling short (1-50 bp) indels
18, as well as local de novo assembly to 
resolve breakpoints for deletions greater than 50 bp.  The latter resulted in a 
doubling of the number of large (> 1 kb) SVs delineated with base pair resolution
19.  
Full genome de novo assembly was also performed (Supplementary Information), 
resulting in the identification of 3.7 Mb of novel sequence not matching the reference 
at a high threshold for assembly quality and novelty. All novel sequence matched 
other human and great ape sequences in the public databases.    
 
Rates of variant discovery 1000 Genomes paper. Last modified on 9/29/2010 
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In the trio project, with an average mapped sequence coverage of 42x per individual 
across six individuals and 2.3 Gb of accessible genome, we identified 5.9 million 
SNPs, 650,000 short indels (of 1-50 bp in length), and over 14,000 larger SVs. In the 
low coverage project, with average mapped coverage of 3.6x per individual across 
179 individuals (Supplementary Fig. 2) and 2.4 Gb of accessible genome, we 
identified 14.4 million SNPs, 1.3 million short indels, and over 20,000 larger SVs.  In 
the exon project, with an average mapped sequence coverage of 56x per individual 
across 697 individuals and a 1.4 Mb target, we identified 12,758 SNPs and 96 indels.   
Experimental validation was used to estimate and control the false discovery rates 
(FDR) for novel variants (Supplementary Table 3). The FDR for each complete call 
set was controlled to be less than 5% for SNPs and short indels, and less than 10% 
for structural variants.  Because in an initial test almost all the sites we called that 
were already in dbSNP validated (285/286), in most subsequent validation 
experiments we only tested novel variants and extrapolated to obtain the overall 
FDR.  The FDR for novel variants was 2.6% for trio SNPs, 10.9% for low coverage 
SNPs, and 1.7% for low coverage indels (Supplementary Material and 
Supplementary Tables 3, 4a and 4b).  This process will underestimate the true FDR 
if more SNPs listed in dbSNP are false positives for some call sets  
Variation detected by the project is not evenly distributed across the genome:  
certain regions, such as the HLA and subtelomeric regions, show high rates of 
variation, while others, for example a 5 Mb gene dense and highly conserved region 
around 3p21, show very low levels of variation (Supplementary Fig. 3a).  At the 
chromosomal scale we see strong correlation between different forms of variation, 
particularly between SNPs and indels (Supplementary Fig. 3b).  However, we also 
find heterogeneity particular to types of SV, for example SVs resulting from nonallelic 
homologous recombination are apparently enriched in the HLA and in subtelomeric 
regions (Supplementary Fig. 3b, top). 
 
Variant Novelty 1000 Genomes paper. Last modified on 9/29/2010 
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As expected, the vast majority of sites variant in any given individual were already 
present in dbSNP; the proportion newly discovered differed substantially among 
populations, variant types and allele frequencies (Fig. 1).  Novel SNPs had a strong 
tendency to be found only in one analysis panel (Fig. 1a).  For SNPs also present in 
dbSNP version 129 (the last release prior to 1000 Genomes Project data), only 25% 
were specific to a single low coverage analysis panel and 56% were found in all 
panels.  On the other hand, 84% of newly discovered SNPs were specific to a single 
analysis panel whereas only 4% were found in all analysis panels. In the exon 
project, where increased depth of coverage and sample size resulted in a higher 
fraction of low frequency variants among discovered sites, 96% of novel variants 
were restricted to samples from a single analysis panel.  In contrast, many novel SVs 
were identified in all analysis panels, reflecting the lower degree of previous 
characterisation (Supplementary Figure 4). 
Populations with African ancestry contributed the largest number of variants and 
contained the highest fraction of novel variants, reflecting the greater diversity in 
African populations.  For example, 63% of novel SNPs in the low coverage project 
and 76% in the exon project were discovered in the African populations, compared to 
20% and 33% in the European ancestry populations for the exon and low coverage 
projects respectively.  
The larger sample sizes in the exon and low coverage projects allowed us to detect 
a large number of low frequency variants (MAF < 5%, Fig. 1b).  Compared to the 
distribution expected from population genetic theory (the neutral coalescent with 
constant population size) we saw an excess of lower frequency variants in the exon 
project, reflecting purifying selection against weakly deleterious mutations and recent 
population growth.  There are signs of a similar excess in the low coverage project 
SNPs, truncated below 5% variant allele frequency by reduction in power of our call 
set to discover variants in this range, as discussed further below.  
As expected, nearly all of the high frequency SNPs discovered here were already 
present in dbSNP; this was particularly true in coding regions (Fig. 1c).  The public 
databases were much less complete for SNPs at low frequencies, for short indels 1000 Genomes paper. Last modified on 9/29/2010 
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and for structural variants (Fig. 1d).  For example, in contrast to coding SNPs (91% 
of common coding SNPs described here were already present in dbSNP), 
approximately 50% of common short indels observed in this project were novel. 
These results are expected given the sample sizes used in the sequencing efforts 
that discovered most of the SNPs previously in dbSNP, and the more limited, and 
lower resolution, efforts to characterize indels and larger structural variation across 
the genome.   
The number of structural variants we observed declined rapidly with increasing 
variant length (Fig. 1d), with notable peaks corresponding to Alus and LINEs.  The 
proportion of larger structural variants that was novel depended markedly on allele 
size, with variants 10 bp to 5 kb in size most likely to be novel (Fig. 1d). This is 
expected, as large (> 5 kb) deletions and duplications were previously discovered 
using array based approaches
14, 20, whereas smaller structural variants (apart from 
polymorphic Alu insertions) had been less well ascertained prior to this study. 
 
Mitochondrial and Y chromosome sequences 
Deep coverage of the mitochondrial genome allowed us to manually curate 
sequences for 163 samples (Supplementary Information).  While variants that were 
fixed within an individual were consistent with the known phylogeny of the 
mitochondrial genome (Supplementary Fig. 5), we found a considerable amount of 
variation within individuals (heteroplasmy).  For example, length heteroplasmy was 
detected in 79% of individuals compared with 52% using capillary sequencing
21, 
largely in the control region (Supplementary Fig. 6a). Base substitution heteroplasmy 
was observed in 45% of samples, seven times higher than reported in the control 
region alone
21, and was spread throughout the molecule (Supplementary Fig. 6b).  
The extent to which this heteroplasmy arose in cell culture remains unknown, but 
appears low (Supplementary Information).   
The Y chromosome was sequenced at an average depth of 1.8x in the 77 males in 
the low coverage project, and 15.2x depth in the two trio fathers. Using customized 1000 Genomes paper. Last modified on 9/29/2010 
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analysis methods (Supplementary Information), we identified 2,870 variable sites, 
74% novel, with 55/56 passing independent validation.  The Y chromosome 
phylogeny derived from the new variants identified novel, well supported clades 
within some of the 12 major haplogroups represented among the samples (e.g., O2b 
in China and Japan; Supplementary Fig. 7).  A striking pattern indicative of a recent 
rapid expansion specific to haplogroup R1b was observed, consistent with the 
postulated Neolithic origin of this haplogroup in Europe
22. 
 
Power to detect variants 
The ability of sequencing to detect a site that is segregating in the population is 
dominated by two factors: whether the nonreference allele is present among the 
individuals chosen for sequencing, and the number of high quality and well mapped 
reads that overlap the variant site in individuals who carry it.  Simple models show 
that for a given total amount of sequencing, the number of variants discovered is 
maximised by sequencing many samples at low coverage
23, 24.  This is because high 
coverage of a few genomes, while providing the highest sensitivity and accuracy in 
genotyping a single individual, involves considerable redundancy and misses 
variation not represented by those samples.  The low coverage project provides us 
with an empirical view of the power of low coverage sequencing to detect variants of 
different types and frequencies.   
Fig. 2a shows the rate of discovery of variants in the CEU samples of the low 
coverage project as assessed by comparison to external data sources: HapMap and 
the exon project for SNPs and array CGH data
20 for large deletions.  We estimate 
that while the low coverage project had only ~25% power to detect singleton SNPs, 
power to detect SNPs present five times in the 120 sampled chromosomes was 
~90% (depending on the comparator), and power was essentially complete for those 
present 10 or more times.  Similar results were seen in the YRI and CHB+JPT 
analysis panels at high allele counts, but slightly worse performance for variants 
present five times (~85% and 75% respectively at HapMap II sites; Supplementary 1000 Genomes paper. Last modified on 9/29/2010 
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Fig. 8). These results suggest that SNP discovery is less affected by the extent of LD 
(which is lowest in the YRI) than sequencing coverage (which was lowest in the CHB 
and JPT).   
For deletions larger than 500 bp, power was approximately 40% for singletons and 
reached 90% for variants present ten times or more in the sample set.  Our use of 
different algorithms for SV discovery ensured that all major mechanistic subclasses 
of deletions were found in our analyses (Supplementary Fig. 9). The lack of 
appropriate comparator datasets for short indels and larger structural variants other 
than deletions prevented a detailed assessment of the power to detect these types of 
variants.  However, power to detect short indels was approximately 70% for variants 
present at least 5 times in the sample, based on the rediscovery of indels in samples 
overlapping with the SeattleSNPs project
25.  Extrapolating from comparisons to Alu 
insertions discovered in the Venter genome
26 suggested an average sensitivity for 
common mobile element insertions of about 75%.  Analysis of a set of duplications
20 
suggested only 30-40% of common duplications were discovered here, mostly as 
deletions with respect to the reference.  Methods capable of discovering inversions 
and novel sequence insertions in low coverage data with comparable specificity 
remain to be developed.   
In summary, low coverage shotgun sequencing provided modest power for 
singletons in each sample (~25-40%), and very good power for variants seen 5 or 
more times in the samples sequenced.  We estimate that there was approximately 
95% power to find SNPs with 5% allele frequency in the sequenced samples, and 
nearly 90% power to find SNPs with 5% allele frequency in populations related by 
1% divergence (Fig. 2b).  Thus we believe the projects found almost all accessible 
common variation in the sequenced populations and the vast majority of common 
variants in closely related populations.   
 1000 Genomes paper. Last modified on 9/29/2010 
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Genotype accuracy 
Genotypes, and, where possible, haplotypes, were inferred for most variants in each 
project (see Supplementary Information, and Table 1).  For the low coverage data, 
statistically phased SNP genotypes were derived by using LD structure in addition to 
sequence information at each site, in part guided by the HapMap 3 phased 
haplotypes.  SNP genotype accuracy varied considerably by pilot, coverage and 
allele frequency. In the low coverage project, the overall genotype error rate (based 
on a consensus of multiple methods) was 1-3% (Fig. 2c, Supplementary Fig. 10).  
The use of HapMap 3 greatly assisted phasing the CEU and YRI samples, for which 
the HapMap 3 genotypes were phased by transmission, but had a more modest 
effect on genotype accuracy away from HapMap 3 sites (for further details see 
Supplementary Material). 
The accuracy at heterozygous sites, a more sensitive measure than overall 
accuracy, was approximately 90% for the lowest frequency variants, increased to 
over 95% for intermediate frequencies and dropped to 70-80% for the highest 
frequency variants (i.e., those where the reference allele is the rare allele).  We note 
that these numbers are derived from sites that can be genotyped using array 
technology, and performance may be lower in harder to access regions of the 
genome.  We find only minor differences in genotype accuracy between populations, 
reflecting differences in coverage as well as haplotype diversity and extent of LD.   
The accuracy of genotypes for large deletions was assessed against previous array 
based analyses
20 (Supplementary Fig. 11).  The genotype error rate across all allele 
frequencies and genotypes was < 1%, with the accuracy of heterozygous genotypes 
at low (MAF < 3%), intermediate (MAF ~50%) and high frequency (MAF > 97%) 
variants estimated at 86%, 97% and 83% respectively.  The greater apparent 
genotype accuracy of structural variants compared to SNPs in the low coverage 
project reflects the increased number of informative reads per individual for variants 
of large size and a bias in the known large deletion genotype set for larger, easier to 
genotype variants. 1000 Genomes paper. Last modified on 9/29/2010 
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For calling genotypes in the low coverage samples, the utility of using LD information 
in addition to sequence data at each site was demonstrated by comparison to 
genotypes of the exon project, which were derived independently for each site using 
high coverage data.  Fig. 2d shows the SNP genotype error rate as a function of 
depth at the genotyped sites in CEU.  A similar number of variants was called, and at 
comparable accuracy, using minimum 4x depth in the low coverage project as was 
obtained with minimum 15x depth in the exon project.  To genotype a high fraction of 
sites both projects needed to make calls at sites with low coverage, and the LD-
based calling strategy for the low coverage project used imputation to make calls at 
nearly 15% more sites with only a modest increase in error rate.  
The accuracy and completeness of the individual genome sequences in the low 
coverage project could be estimated from the trio mothers, each of whom was 
sequenced to high coverage, and for whom data subsampled to 4x were included in 
the low coverage analysis.  Comparison of the SNP genotypes in the two projects 
showed that where the CEU mother had at least one variant allele according to the 
trio analysis, in 96.9% of cases the variant was also identified in the low coverage 
project and in 93.8% of cases the genotype was accurately inferred.  For the YRI trio 
mother the equivalent figures are 95.0% and 88.4% respectively (note that false 
positives in the trio calls will lead to underestimates of the accuracy). 
 
Putative functional variants 
An individual’s genome contains many variants of functional consequence, ranging 
from the beneficial to the highly deleterious.   We estimated that an individual 
typically differs from the reference at 10,000-11,000 nonsynonymous sites 
(sequence differences that lead to differences in the protein sequence) in addition to 
10,000-12,000 synonymous sites (differences in coding exons that do not lead to 
differences in the protein sequence; Table 2).  We found a much smaller number of 
variants likely to have greater functional impact:  in frame indels (190-210), 
premature stop codons (80-100), splice site disrupting variants (40-50), and 1000 Genomes paper. Last modified on 9/29/2010 
17 
 
deletions that shift reading frame (220-250), in each individual.  We estimated that 
each genome is heterozygous for 50-100 variants classified by the Human Gene 
Mutation Database (HGMD) as causing inherited disorders (HGMD-DM). Estimates 
from the different pilot projects were consistent with each other, taking into 
consideration differences in power to detect low frequency variants, fraction of the 
accessible genome and population differences (Table 2), as well as with previous 
observations based on personal genome sequences
10, 11. Collectively, we refer to the 
340-400 premature stops, splice site disruptions and frame shifts, affecting 250-300 
genes per individual, as putative loss of function (LOF) variants.   
In total, we found over 68,300 nonsynonymous SNPs, 34,161 of which were novel 
(Table 2).  In an early analysis, 21,657 nonsynonymous SNPs were validated as 
polymorphic in 620 samples using a custom genotyping array (Table 2; 
Supplementary Information).  The mean minor allele frequency in the array data was 
2.2% for 4,573 novel variants, and 26.2% for previously discovered variants.   
Overall we rediscovered 671 (1.3%) of the 50,361 coding single nucleotide variants 
in HGMD-DM (Supplementary Table 5).  The types of disease for which variants 
were identified were biased towards certain categories (Supplementary Fig. 12), with 
diseases associated with the eye and reproduction significantly over represented 
and diseases of the nervous system significantly under represented.  These biases 
reflect multiple factors including differences in the fitness effects of the variants, the 
extent of medical genetics research and differences in the false reporting rate among 
‘disease causing’ variants.  
As expected, and consistent with purifying selection, putative functional variants had 
an allele frequency spectrum depleted at higher allele frequencies, with putative LOF 
variants showing this effect more strongly (Supplementary Fig. 13).  Of the low 
coverage nonsynonymous, stop-introducing, splice-disrupting and HGMD-DM 
variants, 67.3%, 77.3%, 82.2% and 84.7%, were private to single populations, 
compared to 61.1% for synonymous variants.  Across these same functional classes, 
15.8%, 25.9%, 21.6% and 19.9% of variants were found in only a single individual, 
compared to 11.8% of synonymous variants.  1000 Genomes paper. Last modified on 9/29/2010 
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The tendency for deleterious functional variants to have lower allele frequencies has 
consequences for the discovery and analysis of this type of variation.  In the deeply 
sequenced CEU trio father, who was not included in the low coverage project, 97.8% 
of all single base variants had been found in the low coverage project, but only 95% 
of nonsynonymous, 88% of stop inducing and 85% of HGMD-DM variants.  The 
missed variants correspond to 389 nonsynonymous, 11 stop inducing and 13 
HGMD-DM variants.  As sample size increases, the number of novel variants per 
sequenced individual will decrease, but only slowly.  Analyses based on the exon 
project data (Fig. 3) showed that on average 99% of the synonymous variants in an 
individual would be found in 100 deeply sequenced samples, whereas 250 samples 
would be required to find 99% of nonsynonymous variants and 320 samples would 
still find only 97.4% of the LOF variants present in an individual.  Using detection 
power data from Fig. 2a, we estimated that 250 samples sequenced at low coverage 
would be needed to find 99% of the synonymous variants in an individual, and with 
320 sequenced samples 98.5% of nonsynonymous and 96.3% of LOF variants 
would be found. 
 
 
Application to association studies  
Whole genome sequencing enables all genetic variants present in a sample set to be 
tested directly for association with a given disease or trait.  To quantify the benefit of 
having more complete ascertainment of genetic variation beyond that achievable 
with genotyping arrays, we carried out expression quantitative trait loci (eQTL) 
association tests on the 142 low coverage samples for which expression data are 
available in the cell lines
27.  When association analysis (Spearman rank correlation, 
FDR < 5%, eQTLs within 50 kb of probe) was performed using all sites discovered in 
the low coverage project, a larger number of significant eQTLs (increase of ~20% to 
50%) was observed as compared to association analysis restricted to sites present 
on the Illumina 1M chip (Supplementary Table 6).  The increase was lower in the 1000 Genomes paper. Last modified on 9/29/2010 
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CHB+JPT and CEU samples, where greater LD exists between previously examined 
and newly discovered variants, and higher in the YRI samples, where there are more 
novel variants and less LD.  These results indicate that, while modern genotyping 
arrays capture most of the common variation, there remain substantial additional 
contributions to phenotypic variation from the variants not well captured by the 
arrays. 
Population sequencing of large phenotyped cohorts will allow direct association tests 
for low frequency variants, with a resolution determined by the LD structure.  An 
alternative that is less expensive, albeit less accurate, is to impute variants from a 
sequenced reference panel into previously genotyped samples
28, 29.  We evaluated 
the accuracy of imputation that used the current low coverage project haplotypes as 
the reference panel.  Specifically, we compared genotypes derived by deep 
sequencing of one individual in each trio (the fathers) with genotypes derived using 
the HapMap 3 genotype data (which combined data from the Affymetrix 6.0 and 
Illumina 1M arrays) in those same two individuals and imputation based on the low 
coverage project haplotypes to fill in their missing genotypes.  At variant sites (i.e., 
where the father was not homozygous for the reference), imputation accuracy was 
highest for SNPs at which the minor allele was observed at least 6 times in our low 
coverage samples, with an error rate of ~4% in CEU and ~10% in YRI, and became 
progressively worse for rarer SNPs, with error rates of 35% for sites where the minor 
allele was observed only twice in the low coverage samples (Fig. 4a).   
Although the ability to impute rare variants accurately from the 1000 Genomes 
resource is currently limited, the completeness of the resource nevertheless 
increases power to detect association signals.  To demonstrate the utility of 
imputation in disease samples, we imputed into an eQTL study of ~400 children of 
European ancestry
30 using the low coverage pilot data and HapMap II as reference 
panels.  By comparison to directly genotyped sites we estimated that the effective 
sample size at variants imputed from the pilot CEU low coverage data set is 91% of 
the true sample size for variants with allele frequencies above 10%, 76% in the allele 
frequency range 4-6%, and 54% in the range 1-2%.  Imputing over 6 million variants 
from the low coverage project data increased the number of detected cis-eQTLs by 1000 Genomes paper. Last modified on 9/29/2010 
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~16%, compared to a 9% increase with imputing from HapMap II (FDR 5%, signal 
within 50 kb of transcript; for an example see Fig. 4b).  
In addition to this modest increase in the number of discoveries, testing almost all 
common variants allows identification of many additional candidate variants that 
might underlie each association.  For example, we find that rs11078928, a variant in 
a splice site for GSDMB, is in strong LD with SNPs near ORDML3 previously 
associated with asthma, Crohn’s Disease, Type 1 Diabetes and rheumatoid arthritis, 
thus suggesting the hypothesis that GSDMB could be the causative gene in these 
associations.  Although rs11078928 is not newly discovered, it was not included in 
HapMap or on commercial SNP arrays, and thus could not have been identified as 
associated with these diseases prior to this project.  Similarly, a recent study
31 used 
project data to show that coding variants in APOL1 likely underlie a major risk for 
kidney disease in African Americans previously attributed (at a lower effect size) to 
MYH9.  These examples demonstrate the value of having much more complete 
information on LD, the almost complete set of variants in the regions, and putative 
functional variants in known association intervals. 
Testing almost all common variants also allows us to examine general properties of 
genetic association signals. The NHGRI GWAS catalogue 
(www.genome.gov/gwastudies, accessed July 15, 2010) described 1,227 unique 
SNPs associated with one or more traits (p < 5x10
-8). Of these, 1,185 (96.5%) are 
present in the low coverage CEU dataset.  Under 30% of these are either annotated 
as nonsynonymous variants (77, 6.5%) or in substantial LD (r
2 > 0.5) with a 
nonsynonymous variant (272, 23%). In the latter group, only 93 (8.4%) are in strong 
LD (r
2 > 0.9) with a nonsynonymous variant.  Since we tested ~95% of common 
variation, these results suggest that no more than a third of complex trait association 
signals are likely to be caused by common coding variation.  Although it remains to 
be seen whether reported associations are better explained through weak LD to 
coding variants with strong effects, these results are consistent with the view that 
most contributions of common variation to complex traits are regulatory in nature. 
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Mutation, recombination and natural selection 
Project sequence data allowed us to investigate fundamental processes that shape 
human genetic variation including mutation, recombination and natural selection. 
 
Detecting de novo mutations in trio samples 
Deep sequencing of individuals within a pedigree offers the potential to detect de 
novo germline mutation events. Our approach was to allow a relatively high false 
discovery rate in an initial screen to capture a large fraction of true events and then 
use a second technology to rule out false positive mutations. 
In the CEU and YRI trios respectively, 3,236 and 2,750 candidate de novo germline 
single base mutations were selected for further study, based on their presence in the 
child but not the parents.  Of these, 1,001 (CEU) and 669 (YRI) were validated by 
resequencing the cell line DNA.  When these were tested for segregation to offspring 
(CEU) or in non-clonal DNA from whole blood (YRI), only 49 CEU and 35 YRI 
candidates were confirmed as true germline mutations. Correcting for the fraction of 
the genome accessible to this analysis provided an estimate of the per generation 
base pair mutation rate of 1.2x10
-8 and 1.0x10
-8 in the CEU and YRI trios 
respectively.  These values are similar to estimates obtained from indirect 
evolutionary comparisons
32, direct studies based on pathogenic mutations
33, and a 
recent analysis of a single family
34.   
We infer that the remaining vast majority (952 CEU and 634 YRI) of the validated 
variants were somatic or cell line mutations.  The greater number of  these validated 
non-germline mutations in the CEU cell line perhaps reflects the greater age of the 
CEU cell culture. Across the two trio offspring, we observed a single, synonymous, 
coding germline mutation, and 17 coding non-germline mutations of which 16 were 
nonsynonymous, perhaps suggesting selection during cell culture. 1000 Genomes paper. Last modified on 9/29/2010 
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Although the number of non-germline variants found per individual is a very small 
fraction of the total number of variants per individual (~0.03% for the CEU child and 
~0.02% for the YRI child), these variants will not be shared between samples. 
Assuming that the number of non-germline mutations in these two trios is 
representative of all cell line DNA we analysed, we estimate that non-germline 
mutations might constitute 0.36% and 2.4% of all variants, and 0.61% and 3.1% of 
functional variants, in the low coverage and exon pilots respectively.   In larger 
samples of thousands the overall false positive rates from cell line mutations would 
become significant, and confound interpretation, suggesting that large scale studies 
should use DNA from primary tissue such as blood where possible.  
 
Constraint around genes and the effects of selection on local variation 
Natural selection can affect levels of DNA variation across genes in multiple ways: 
strongly deleterious mutations will be rapidly eliminated by natural selection, weakly 
deleterious mutations can segregate in populations but rarely become fixed, and 
selection at nearby sites (both purifying and adaptive) can reduce genetic variation 
through background selection
35 and the hitchhiking effect
36.  The effect of these 
different forces on genetic variation can be disentangled by examining patterns of 
diversity and divergence within and around known functional elements.  The low 
coverage data enables, for the first time, genome wide analysis of such patterns in 
multiple populations.  Fig. 5a (top) shows the pattern of diversity relative to genic 
regions measured by aggregating estimates of heterozygosity around protein coding 
genes.  Within genes, exons harbor the least diversity (about 50% of that of introns) 
and 5’ and 3’ UTRs harbor slightly less diversity than immediate flanking regions and 
introns.  However, this variation in diversity is fully explained by the level of 
divergence (Fig. 5a lower) consistent with the common part of the allele frequency 
spectrum being dominated by effectively neutral variants, and weakly deleterious 
variants contributing only to the rare end of the frequency spectrum. 1000 Genomes paper. Last modified on 9/29/2010 
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In contrast, diversity in the immediate vicinity of genes (scaled by divergence) is 
reduced by approximately 10% relative to sites distant from any gene (Fig 5b). 
Although a similar reduction has been seen previously in gene dense regions
37, 
project data enable the scale of the effect to be determined.  We find that the 
reduction extends up to 0.1cM away from genes, typically 85 kb, suggesting that 
selection at linked sites restricts variation relative to neutral levels across the majority 
of the human genome. 
 
Positive selection and the distribution of genetic variation among 
populations 
Previous inferences about demographic history and the role of local adaptation in 
shaping human genetic variation made from genome wide genotype data
4, 38, 39 have 
been limited by the partial and complex ascertainment of SNPs on genotype arrays.  
While data from the 1000 Genome Project pilots are neither fully comprehensive nor 
fully free of ascertainment bias (issues include low power for rare variants, noise in 
allele frequency estimates, some false positives, non-random data collection across 
samples, platforms and populations, and the use of imputed genotypes), they can be 
used to address key questions about the extent of differentiation among populations, 
the presence of highly differentiated variants and the ability to fine map signals of 
local adaptation. 
Although the average level of population differentiation is low (at sites genotyped in 
all populations the mean value of Wright’s Fst is 0.071 between CEU and YRI, 0.083 
between YRI and CHB+JPT and 0.052 between CHB+JPT and CEU), we find 
several hundred thousand SNPs with large allele frequency differences in each 
population comparison (Fig. 5c).  As seen in previous studies
4, 39, the most highly 
differentiated sites were enriched for nonsynonymous variants, suggestive of the 
action of local adaptation.  The completeness of common variants in the low 
coverage resource enables new perspectives in the search for local adaptation.  
First, it provides a more comprehensive catalogue of fixed differences between 1000 Genomes paper. Last modified on 9/29/2010 
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populations, of which there are very few:  two between CEU and CHB+JPT 
(including the A111T missense variant in SLC24A5
40 contributing to light skin 
colour), four between CEU and YRI (including the -46 GATA box null mutation 
upstream of DARC
41, the Duffy O allele leading to vivax malaria resistance) and 72 
between CHB+JPT and YRI (including 24 around the exocyst complex component 
gene EXOC6B); see Supplementary Table 7 for a complete list.  Second, it provides 
new candidates for selected variants, genes and pathways.  For example, we 
identified 139 nonsynonymous (NS) variants showing large allele frequency 
differences (at least 0.8) between populations (Supplementary Table 8), including at 
least two genes involved in meiotic recombination, FANCA (9th most extreme NS 
SNP in CEU vs CHB+JPT) and TEX15 (13th most extreme NS SNP in CEU vs YRI, 
and 26th most extreme NS SNP in CHB+JPT vs YRI). Because we are finding 
almost all common variants in each population, these lists should contain the vast 
majority of the near fixed differences among these populations.  Finally, it improves 
the fine mapping of selective sweeps (Supplementary Fig. 14) and analysis of the 
dynamics of location adaptation.  For example, we find that the signal of population 
differentiation around high Fst genic SNPs drops by half within, on average, less 
than 0.05 cM (typically 30-50 kb; Fig 5d).  Furthermore, 51% of such variants are 
polymorphic in both populations.  These observations suggest that much local 
adaptation has occurred by selection acting on existing variation rather than new 
mutation. 
 
The effect of recombination on local sequence evolution 
We estimated a fine-scale genetic map from the phased low coverage genotypes.  
Recombination hotspots were narrower than previously estimated
4 (mean hotspot 
width of 2.3 kb compared to 5.5 kb in HapMap II; Fig. 6a), although, unexpectedly, 
the estimated average peak recombination rate in hotspots is lower in YRI (13 
cM/Mb) than in CEU and CHB+JPT (20cM/Mb).  In addition, crossover activity is less 
concentrated in the genome in YRI, with 70% of recombination occurring in 10% of 
the sequence rather than 80% of the recombination for CEU and CHB+JPT (Fig. 6b).  1000 Genomes paper. Last modified on 9/29/2010 
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A possible biological basis for these differences is that PRDM9, which binds a DNA 
motif strongly enriched in hotspots and influences the activity of LD-defined 
hotspots
43-46 , shows length variation in its DNA binding zinc fingers within 
populations, and substantial differentiation between African and non-African 
populations, with a greater allelic diversity in Africa
46.  This could mean greater 
diversity of hotspot locations within Africa and therefore a less concentrated picture 
in this data set of recombination and lower usage of LD-defined hotspots (which 
require evidence in at least two populations and therefore will not reflect hotspots 
present only in Africa). 
The low coverage data also allowed us to address a longstanding debate about 
whether recombination has any local mutagenic effect.  Direct examination of 
diversity around hotspots defined from LD data is potentially biased (because the 
detection of hotspots requires variation to be present), but we can without bias 
examine rates of SNP variation and recombination around the PRDM9 binding motif 
associated with hotspots.  Fig. 6c shows the local recombination rate and pattern of 
SNP variation around the motif compared to the same plots around a motif that is a 
single base difference away.  While the motif is associated with a sharp peak in 
recombination rate, there is no systematic effect on local rates of SNP variation.  We 
infer that, although recombination may influence the fate of new mutations, for 
example through biased gene conversion, there is no evidence that it influences the 
rate at which new variants appear. 
 
Discussion 
The 1000 Genomes Project launched in 2008 with the goal of creating a public 
reference database for DNA polymorphism that is 95% complete at allele frequency 
1%, and more complete for common variants and exonic variants, in each of multiple 
human population groups.  The three pilot projects described here were designed to 
develop and evaluate methods to use high throughput sequencing to achieve these 
goals.  The results indicate (a) that robust protocols now exist for generating both 1000 Genomes paper. Last modified on 9/29/2010 
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whole genome shotgun and targeted sequence data, (b) that algorithms to detect 
variants from each of these designs have been validated and (c) that low coverage 
sequencing offers an efficient approach to detect variation genome wide, whereas 
targeted sequencing offers an efficient approach to detect and accurately genotype 
rare variants in regions of functional interest (such as exons).  
Data from the pilot projects are already informing medical genetic studies.  As shown 
in our analysis of prior eQTL datasets, a more complete catalogue of genetic 
variation can identify signals previously missed and dramatically increase the 
number of identified candidate functional alleles at each locus.  Project data have 
been used to impute over 6 million genetic variants into GWAS, for traits as diverse 
as smoking
47 and multiple sclerosis
48, as an exclusionary filter in Mendelian disease 
studies
49 and tumor sequencing studies, and to design the next generation of 
genotyping arrays.  
The results from this study also provide a template for future genome-wide 
sequencing studies on larger sample sets.  Our plans for achieving the 1000 
Genomes Project goals are described in Box 2.  Other studies using phenotyped 
samples are already using components of the design and analysis framework 
described above. 
Measurement of human DNA variation is an essential prerequisite for carrying out 
human genetics research. The 1000 Genomes Project represents a step towards a 
complete description of human DNA polymorphism.  The larger dataset provided by 
the full 1000 Genomes Project will allow more accurate imputation of variants in 
GWAS and thus better localization of disease associated variants.  The project will 
provide a template for studies using genome wide sequence data.  Applications of 
these data, and the methods developed to generate them, will contribute to a much 
more comprehensive understanding of the role of inherited DNA variation in human 
history, evolution and disease.  1000 Genomes paper. Last modified on 9/29/2010 
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Box 2.  Design of the Full 1000 Genomes Project  
The production phase of the full 1000 Genomes Project will combine low coverage 
whole genome sequencing, array based genotyping, and deep targeted sequencing 
of all coding regions in 2,500 individuals from five large regions of the world (five 
population samples of 100 in or with ancestry from each of Europe, East Asia, South 
Asia and West Africa, and seven populations totalling 500 from the Americas; 
Supplementary Table 9).  We will increase the low coverage average depth to over 
4x per individual, and use blood derived DNA where possible to minimise somatic 
and cell line false positives.  
A clustered sampling approach was chosen to improve low frequency variant 
detection in comparison to a design in which a smaller number of populations were 
sampled to a greater depth. In a region containing a cluster of related populations, 
genetic drift can lead variants that are at low frequency overall to be more common 
(hence easily detectable) in one population but less common (hence likely to be 
undetectable) in another.  We  modelled this process using project data (see 
Supplementary Information) assuming that five sampled populations are equally 
closely related to each other (Fst = 1%).  We found that the low coverage 
sequencing in this design would discover 95% of variants in the accessible genome 
at 1% frequency across each broad geographic region, between 90% and 95% of 
variants at 1% frequency in any one of the sampled populations and about 85% of 
variants at 1% frequency in any equally related but unsampled population.  The chart 
shows predicted discovery curves for variants at different frequencies with details as 
for Fig. 2b.  The model is conservative, in that it ignores migration and the 
contribution to discovery from more distantly related populations, each of which will 
increase sensitivity for variants in any given population.  In exons, the full project 
should have 95% power to detect variants at a frequency of 0.3% and approximately 
60% power for variants at a frequency of 0.1%. 1000 Genomes paper. Last modified on 9/29/2010 
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In addition to improved detection power, we expect the full project to have increased 
genotype accuracy due to (a) advances in sequencing technology that are reducing 
per base error rates and alignment artefacts, (b) increased sample size, which 
improves imputation based methods, (c) ongoing algorithmic improvements, and (d) 
the designing by the project of genotyping assays that will directly genotype up to 10 
million common and low frequency variants (SNPs, indels and SVs) observed in the 
low coverage data.  In addition, we expect the fraction of the genome that is 
accessible to increase.  Longer read lengths, improved protocols for generating 
paired reads, and the use of more powerful assembly and alignment methods are 
expected to increase accessibility from 80-85% to above 90% of the reference 
genome (Supplementary Fig. 15).  
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Figure Legends 
 
Figure 1:  Properties of the variants found.  a, Venn diagrams showing the 
numbers of SNPs identified in each pilot project in each population or analysis panel, 
subdivided according to whether the SNP was present in dbSNP release 129 
(“Known”) or not (“Novel”).  Exon analysis panel AFR is YRI+LWK, ASN is 
CHB+CHD+JPT, and EUR is CEU+TSI.  Note that the scale for the exon project 
column is much larger than for the other pilots.  b, The number of variants per Mb at 
different allele frequencies divided by the expectation under the neutral coalescent 
(1/i, where i is the variant allele count), thus giving an estimate of theta per 
megabase.   Blue: low coverage SNPs, red: low coverage indels, black: low 
coverage genotyped large deletions, green: exon SNPs. The spikes at the right ends 
of the lines correspond to excess variants for which all samples differed from the 
reference (approximately 1 per 30 kb), consistent with errors in the reference 
sequence. c, Fraction of variants in each allele frequency class that were novel. 
Novelty was determined by comparison to dbSNP release 129 for SNPs and small 
indels, dbVar (June 2010) for deletions, and two published genomes
10, 11 for larger 
indels.  d, Size distribution and novelty of variants discovered in the low coverage 
project.  SNPs are shown in blue, deletions with respect to the reference sequence 
in red, and insertions or duplications with respect to the reference in green. The 
fraction of variants in each size bin that were novel is shown by the purple line, and 
is defined relative to dbSNP (SNPs and indels), dbVar (deletions, duplications, 
mobile element insertions), dbRIP and other studies
50 (mobile element insertions), 
Venter and Watson genomes
10, 11 (short indels and large deletions), and short indels 
from split capillary reads
51. To account for ambiguous placement of many indels, 
discovered indels were deemed to match known indels if they were within 25 bp of a 
known indel of the same size. To account for imprecise knowledge of the location of 
most deletions and duplications, discovered variants were deemed to match known 
variants if they had > 50% reciprocal overlap. 
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Figure 2:  Variant discovery rates and genotype accuracy in the low coverage 
project.  a, Rates of low coverage variant detection by allele frequency in CEU. 
Lines show the fraction of variants seen in overlapping samples in independent 
studies, that were also found to be polymorphic in the low coverage project (in the 
same overlapping samples), as a function of allele count in the 60 low coverage 
samples. Note that we plot power against expected allele count in 60 samples, e.g. a 
variant present in, say, 2 copies in an overlap of 30 samples is expected to be 
present 4 times in 60 samples. The crosses on the right represent the average 
discovery fraction for all variants having more than 10 copies in the sample. Colours 
correspond to: (red) HapMap II sites, excluding sites also in HapMap 3 (43 
overlapping samples); (blue) exon project sites (57 overlapping samples); (green) 
deletions from Conrad et al.
20 (60 overlapping samples; deletions were classified as 
“found” if there was any overlap).  Error bars show 95% confidence interval.  b, 
Estimated rates of discovery of variants at different frequencies in the CEU (blue), a 
population related to the CEU with Fst = 1% (green) and across Europe as a whole 
(light blue).  The insert shows a cartoon of the statistical model for population history 
and thus allele frequencies in related populations where an ancestral population 
gave rise to many equally related populations, one of which (blue circle) has samples 
sequenced.  c, SNP genotype accuracy by allele frequency in the CEU low coverage 
project, measured by comparison to HapMap II genotypes at sites present in both 
call sets, excluding sites that were also in HapMap 3.  Lines represent the average 
accuracy of homozygote reference (red), heterozygote (green) and homozygote 
alternative calls (blue) as a function of the alternative allele count in the overlapping 
set of 43 samples, and the overall genotype error rate (grey, at bottom of plot). The 
inset shows the number of each genotype class as a function of alternative allele 
count.  d,  Coverage and accuracy for the low coverage and exon projects as a 
function of depth threshold.  For 41 CEU samples sequenced in both the exon and 
low coverage projects, on the x axis is shown the number of non-reference SNP 
genotype calls at HapMap II sites not in HapMap 3 that were called in the exon 
project target region, and on the y axis is shown the number of these calls that were 
not variant (i.e., are reference homozygote and thus incorrectly were called as 
variant) according to HapMap II.  Each point plotted corresponds to a minimum 1000 Genomes paper. Last modified on 9/29/2010 
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depth threshold for called sites.  Grey lines show constant error rates.  The exon 
project calls (red) were made independently per sample, whereas the low coverage 
calls (blue), which were only slightly less accurate, were made using LD information 
that combined partial information across samples and sites in an imputation-based 
algorithm. The additional data added from point “1” to point “0” (upper right in the 
figure) for the low coverage project were completely imputed. 
 
Figure 3.  The value of additional samples for variant discovery.  The fraction of 
variants present in an individual that would not have been found in a sequenced 
reference panel, as a function of reference panel size and the sequencing strategy.  
The lines represent predictions for Synonymous (Syn), Nonsynonymous (NonSyn), 
and Loss of function (LOF) variant classes, broken down by sequencing category:  
full sequencing as for exons (Full) and low coverage sequencing (LowCov).  The 
values were calculated from observed distributions of variants of each class in 321 
East Asian samples (CHB, CHD and JPT populations) in the exon data, and power 
to detect variants at low allele counts in the reference panel from Figure 2a. 
 
Figure 4:  Imputation from the low coverage data.  a, Accuracy of imputing variant 
genotypes using HapMap 3 sites to impute sites from the low coverage (LC) project 
into the trio fathers as a function of allele frequency.  Accuracy of imputing 
genotypes from the HapMap II reference panels
4 is also shown.  Imputation 
accuracy for common variants was generally a few percent worse from the low 
coverage project than from HapMap, although error rates increase for less common 
variants.  b, An example of imputation in a cis-eQTL for TIMM22, for which the 
original Ilumina 300K genotype data gave a weak signal
30.  Imputation using 
HapMap data made a small improvement, and imputation using low coverage 
haplotypes provided a much stronger signal. 
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Figure 5:  Variation around genes. a, Diversity in genes calculated from the CEU 
low coverage genotype calls (upper) and diversity divided by divergence between 
humans and rhesus macaque (lower).  Within each element averaged diversity is 
shown for the first and last 25 base pairs, with the remaining 150 positions sampled 
at fixed distances across the element (elements shorter than 150 base pairs were 
not considered). Note that estimates of diversity will be reduced compared to the true 
population value due to the reduced power for rare variants, but relative values 
should be little affected.  b, Average autosomal diversity divided by divergence, as a 
function of genetic distance from coding transcripts, calculated at putatively neutral 
sites, i.e., excluding phastcons conserved noncoding sequences and all sites in 
coding exons but four-fold degenerate sites. c, Numbers of SNPs showing 
increasingly high levels of differentiation in allele frequency between the CEU and 
CHB+JPT (red), CEU and YRI (green) and CHB+JPT and YRI (blue).  Lines indicate 
synonymous variants (dashed), nonsynonymous variants (dotted) and other variants 
(solid).  The most highly differentiated genic SNPs were enriched for 
nonsynonymous variants, indicating local adaptation.  d, The decay of population 
differentiation around genic SNPs showing extreme allele frequency differences 
between populations (difference in frequency of at least 0.8 between populations, 
thinned so there is no more than one per gene considered; Supplementary Table 8).  
For all such SNPs the highest allele frequency difference in bins of 0.01 cM away 
from the variant was recorded and averaged.   
 
Figure 6:  Recombination.  a, Improved resolution of hotspot boundaries. The 
average recombination rate estimated from low coverage project data around 
recombination hotspots detected in HapMap II.  Recombination hotspots were 
narrower, and in CEU (orange) and CHB+JPT (purple) more intense than previously 
estimated.  b, The concentration of recombination in a small fraction of the genome, 
one line per chromosome. If recombination were uniformly distributed throughout the 
genome, then the lines on this figure would appear along the diagonal. Instead, most 
recombination occurs in a small fraction of the genome. Recombination rates in YRI 
(green) appeared to be less concentrated in recombination hotspots than CEU 1000 Genomes paper. Last modified on 9/29/2010 
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(orange) or CHB+JPT (purple).  HapMap II estimates are shown in black.  c, The 
relationship between genetic variation and recombination rates in the YRI population. 
The top plot shows average levels of diversity, measured as mean number of 
segregating sites per base, surrounding occurrences of the previously described 
hotspot motif 
43 (CCTCCCTNNCCAC, red line) and a closely related, but not 
recombinogenic DNA sequence (CTTCCCTNNCCAC, green line). The lighter red 
and green shaded areas give 95% confidence intervals on diversity levels. The 
bottom plot shows estimated mean recombination rates surrounding motif 
occurrences, with colours defined as in the top plot. 
 
 Table 1 - Variants discovered by pilot, type, population and novelty. 
   Low coverage  Trios  Exon  Union 
   CEU YRI  CHB+JPT  Total  CEU  YRI  Total  Total  Total 
Samples  60  59 60  179  3  3  6  697 742 
Total raw bases (Gb)  1401.56  874.40  595.93  2871.89  560.38  614.63  1175.01  845.40  4892.30 
Total mapped bases (Gb)  817.46  595.58  468.17  1881.20  368.89  342.47  711.36  55.74  2648.29 
Mean mapped depth (x)  4.62  3.42  2.65  3.56  43.14  40.05  41.60  55.92  N/A 
Fraction of genome called  2.43 Gb 
(86%) 
2.39 Gb 
(85%) 
2.41 Gb 
(85%) 
2.42 Gb 
(86.0%) 
2.26 Gb 
(79%) 
2.21 Gb 
(78%) 
2.24 Gb 
(79%) 
1.4 Mb  N/A 
No. of SNPs 
(% novel) 
7,943,827 
(33%) 
10,938,130 
(47%) 
6,273,441 
(28%) 
14,894,361 
(54%) 
3,646,764 
(11%) 
4,502,439 
(23%) 
5,907,699 
(24%) 
12,758 
(70%) 
15,275,256 
(55%) 
Variant SNP sites / individual  2,918,623  3,335,795  2,810,573  3,019,909  2,741,276  3,261,036  3,001,156  763  N/A 
No. of indels 
(% novel) 
728,075 
(39%) 
941,567 
(52%) 
666,639 
(39%) 
1,330,158 
(57%) 
411,611 
(25%) 
502,462 
(37%) 
682,148 
(38%) 
96 (72%)  1,480,877 
(57%) 
Variant indel sites / individual  354,767  383,200  347,400  361,669  322,078  382,869  352,474  1  N/A 
No. of deletions 
(% novel) 
N/D N/D  N/D  15,893 
(60%) 
6,593 
(41%) 
8,129 
(50%) 
11,248 
(51%) 
N/D 22,025 
(61%) 
No. of genotyped deletions 
(% novel) 
N/D N/D  N/D  10,742 
(57%) 
N/D N/D  6,317 
(48%) 
N/D 13,826 
(58%) 
No. of duplications 
(% novel) 
259 
(90%) 
320 
(90%) 
280 
(91%) 
407 
(89%) 
187 
(93%) 
192 
(91%) 
256 
(92%) 
N/D 501 
(89%) 
No. of mobile element insertions 
(% novel) 
3,202 
(79%) 
3,105 
(84%) 
1,952 
(76%) 
4,775 
(86%) 
1,397 
(68%) 
1,846 
(78%) 
2,531 
(78%) 
N/D 5,371 
(87%) 
No. of novel sequence insertions 
(% novel) 
N/D N/D  N/D  N/D  111 
(96%) 
66 
(86%) 
174 
(93%) 
N/D 174 
(93%) 
    
   Exon populations    
   CEU TSI LWK YRI CHB  CHD  JPT    
Samples  90  66 108  112 109 107  105    
Total collected bases (Gb)  151.15  63.96  53.42  146.52  93.08  126.59  210.68     
Mean mapped depth on target (x)  73  71  32  62  47  62  53     
No. of SNPs (% novel)  3,489 (34%)  3,281 (34%)  5,459 (50%)  5,175 (46%)  3,415 (47%)  3,431 (50%)  2,900 (42%)     
Variant SNP sites / individual  715  727  902  794  713  770  694     
No. of indels (No. novel)  24 (9)  24 (10)  24 (15)  38 (18)  31 (14)  26 (11)  27 (11)     
Variant indel sites / individual  3  3  3  3  3  2  3     
 Table 2 - Estimated numbers of potentially functional variants in genes. 
 
   Combined  Combined  Low Coverage  High-Coverage Trio  Exon Capture 
class total  novel  Total  Interquartile
a total individual  range  total  interquartile
a GENCODE  extrap. 
synonymous SNPs  60157  23498  55217  10572-12126  21410  9193-12500  5708  461-532  11553-13333 
nonsynonymous SNPs  68300  34161  61284  9966-10819  19824  8299-10866  7063  396-441  9924-11052 
small in-frame indels  714  383  666  198-205  289  130-178  59  1-3  ~25-75 
stop  losses  77 40  71  9-11  22 4-14 6  0-0  ~0-0 
stop-introducing SNPs  1057  755  951  88-101  192  67-100  82  2-3  ~50-75 
splice-site-disrupting  SNPs 517 399  500  41-49  82 28-45 3  1-1  ~50 
small  frameshift  indels  954  551  890 227-242 433  192-280  37  0-1  ~0-25 
genes disrupted by large deletions  147  71  143  28-36  82  33-49  NA  NA  NA 
total genes containing LOF variants  2304  NA  1795  272-297  483  240-345  77  3-4  ~75-100 
HGMD "damaging mutation" SNPs  671  NA  578  57-80  161  48-82  99  2-4  ~50-100 
aInterquartile range of number of variants of type per individual Figure Box 1
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